Literature DB >> 19731079

Frequent alterations of the PI3K/AKT/mTOR pathways in hereditary nonpolyposis colorectal cancer.

Anna Isinger Ekstrand1, Mats Jönsson, Annika Lindblom, Ake Borg, Mef Nilbert.   

Abstract

The phosphatidylinositol 3-kinases-AKT-mammalian target of rapamycin pathway (PI3K/AKT/mTOR) is central in colorectal tumors. Data on its role in hereditary cancers are, however, scarce and we therefore characterized mutations in PIK3CA and KRAS, and expression of PIK3CA, phosphorylated AKT, and PTEN in colorectal cancers linked to hereditary nonpolyposis colorectal cancer (HNPCC). Sequencing was used to identify mutations in PIK3CA, a real-time PCR-based method to identify KRAS mutations, and immunohistochemical staining was used to evaluate the expression of PIK3CA, phosphorylated AKT and PTEN in 58 HNPCC-associated colorectal cancers. Derangements of at least one of the PI3K/AKT/mTOR components analyzed were found in 51/58 (88%) tumors. Mutations in PIK3CA and KRAS were identified in 14 and 31% of the tumors respectively. Overexpression of PIK3CA and phosphorylated AKT occurred in 59 and 75% and were strongly associated (P = 0.005). Reduced/lost PTEN expression was found in 63% of the tumors. Though HNPCC-associated colorectal cancers show simple genetic profiles with few chromosomal alterations, we demonstrate frequent and repeated targeting of the PI3K/AKT/mTOR pathway, which suggests that therapeutic strategies directed at this pathway are likely to be beneficial also in HNPCC.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19731079     DOI: 10.1007/s10689-009-9293-1

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  28 in total

Review 1.  The phosphatidylinositol 3-Kinase AKT pathway in human cancer.

Authors:  Igor Vivanco; Charles L Sawyers
Journal:  Nat Rev Cancer       Date:  2002-07       Impact factor: 60.716

2.  Protein expression and prognostic value of genes in the erb-b signaling pathway in advanced ovarian carcinomas.

Authors:  Yun Wang; Gunnar B Kristensen; Aslaug Helland; Jahn M Nesland; Anne-Lise Børresen-Dale; Ruth Holm
Journal:  Am J Clin Pathol       Date:  2005-09       Impact factor: 2.493

Review 3.  Classification of colorectal cancer based on correlation of clinical, morphological and molecular features.

Authors:  J R Jass
Journal:  Histopathology       Date:  2007-01       Impact factor: 5.087

4.  Cancer-specific mutations in PIK3CA are oncogenic in vivo.

Authors:  Andreas G Bader; Sohye Kang; Peter K Vogt
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-23       Impact factor: 11.205

Review 5.  Hereditary polyposis syndromes and hereditary non-polyposis colorectal cancer.

Authors:  Brian A Allen; Jonathan P Terdiman
Journal:  Best Pract Res Clin Gastroenterol       Date:  2003-04       Impact factor: 3.043

6.  New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC.

Authors:  H F Vasen; P Watson; J P Mecklin; H T Lynch
Journal:  Gastroenterology       Date:  1999-06       Impact factor: 22.682

7.  PIK3CA mutation is predictive of poor survival in patients with colorectal cancer.

Authors:  Shunsuke Kato; Satoru Iida; Tetsuro Higuchi; Toshiaki Ishikawa; Yoko Takagi; Masamichi Yasuno; Masayuki Enomoto; Hiroyuki Uetake; Kenichi Sugihara
Journal:  Int J Cancer       Date:  2007-10-15       Impact factor: 7.396

8.  PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations.

Authors:  Katsuhiko Nosho; Takako Kawasaki; Mutsuko Ohnishi; Yuko Suemoto; Gregory J Kirkner; Dimity Zepf; Liying Yan; Janina A Longtine; Charles S Fuchs; Shuji Ogino
Journal:  Neoplasia       Date:  2008-06       Impact factor: 5.715

9.  Microsatellite instability is associated with tumors that characterize the hereditary non-polyposis colorectal carcinoma syndrome.

Authors:  P Peltomäki; R A Lothe; L A Aaltonen; L Pylkkänen; M Nyström-Lahti; R Seruca; L David; R Holm; D Ryberg; A Haugen
Journal:  Cancer Res       Date:  1993-12-15       Impact factor: 12.701

10.  Mutations of the PIK3CA gene in hereditary colorectal cancers.

Authors:  Michiko Miyaki; Takeru Iijima; Tatsuro Yamaguchi; Keiichi Takahashi; Hiroshi Matsumoto; Michiya Yasutome; Nobuaki Funata; Takeo Mori
Journal:  Int J Cancer       Date:  2007-10-01       Impact factor: 7.396

View more
  30 in total

1.  ARK5 is associated with the invasive and metastatic potential of human breast cancer cells.

Authors:  Xin-Zhong Chang; Jie Yu; Hai-Yin Liu; Rui-Hua Dong; Xu-Chen Cao
Journal:  J Cancer Res Clin Oncol       Date:  2011-11-22       Impact factor: 4.553

Review 2.  Targeting mTOR network in colorectal cancer therapy.

Authors:  Xiao-Wen Wang; Yan-Jie Zhang
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

3.  PIK3CA mutations in KRAS and BRAF wild type colorectal cancer patients. A study of Spanish population.

Authors:  Marta Herreros-Villanueva; Noemí Gomez-Manero; Pilar Muñiz; Carlos García-Girón; Maria Jesús Coma del Corral
Journal:  Mol Biol Rep       Date:  2010-06-23       Impact factor: 2.316

4.  Hsa-miR-137, hsa-miR-520e and hsa-miR-590-3p perform crucial roles in Lynch syndrome.

Authors:  Changyu Zhou; Jiayu Li; Jiarui Li; Yingchun Wan; Tao Li; Piyong Ma; Yingjian Wang; Haiyan Sang
Journal:  Oncol Lett       Date:  2016-07-06       Impact factor: 2.967

Review 5.  Updates of mTOR inhibitors.

Authors:  Hongyu Zhou; Yan Luo; Shile Huang
Journal:  Anticancer Agents Med Chem       Date:  2010-09       Impact factor: 2.505

6.  A colon cancer-derived mutant of Krüppel-like factor 5 (KLF5) is resistant to degradation by glycogen synthase kinase 3β (GSK3β) and the E3 ubiquitin ligase F-box and WD repeat domain-containing 7α (FBW7α).

Authors:  Agnieszka B Bialkowska; Yang Liu; Mandayam O Nandan; Vincent W Yang
Journal:  J Biol Chem       Date:  2014-01-07       Impact factor: 5.157

7.  Functional mechanism of the enhancement of 5-fluorouracil sensitivity by TUSC4 in colon cancer cells.

Authors:  Ming-Na Liu; Ai-Yun Liu; Feng-Hua Pei; Xiao Ma; Yu-Jing Fan; Ya-Ju DU; Bing-Rong Liu
Journal:  Oncol Lett       Date:  2015-10-13       Impact factor: 2.967

8.  Deranged Wnt signaling is frequent in hereditary nonpolyposis colorectal cancer.

Authors:  Anna Isinger-Ekstrand; Christina Therkildsen; Inge Bernstein; Mef Nilbert
Journal:  Fam Cancer       Date:  2011-06       Impact factor: 2.375

9.  Inhibition of AMPK-related kinase 5 (ARK5) enhances cisplatin cytotoxicity in non-small cell lung cancer cells through regulation of epithelial-mesenchymal transition.

Authors:  Minghui Li; Chengfei Zheng; Hongfei Xu; Wei He; Yongchun Ruan; Jianyong Ma; Junnan Zheng; Chengmeng Ye; Weidong Li
Journal:  Am J Transl Res       Date:  2017-04-15       Impact factor: 4.060

10.  Tandutinib inhibits the Akt/mTOR signaling pathway to inhibit colon cancer growth.

Authors:  Sivapriya Ponnurangam; David Standing; Parthasarathy Rangarajan; Dharmalingam Subramaniam
Journal:  Mol Cancer Ther       Date:  2013-02-20       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.